within Pharmacolibrary.Drugs.ATC.A;

model A02BC03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 2.3333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600,            
    Vdp             = 0.015,
    k12             = 2.1,
    k21             = 2.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BC03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lansoprazole is a proton pump inhibitor (PPI) used to reduce gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. Lansoprazole is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects, following single oral administration in fasting state.</p><h4>References</h4><ol><li><p>Hanif, N, et al., &amp; Rasool, MF (2023). Clinical pharmacokinetics of nebivolol: a systematic review. <i>Drug metabolism reviews</i> 55(4) 428–440. DOI:<a href=&quot;https://doi.org/10.1080/03602532.2023.2271195&quot;>10.1080/03602532.2023.2271195</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37849071/&quot;>https://pubmed.ncbi.nlm.nih.gov/37849071</a></p></li><li><p>Landes, BD, et al., &amp; Flouvat, B (1995). Clinical pharmacokinetics of lansoprazole. <i>Clinical pharmacokinetics</i> 28(6) 458–470. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199528060-00004&quot;>10.2165/00003088-199528060-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7656504/&quot;>https://pubmed.ncbi.nlm.nih.gov/7656504</a></p></li><li><p>Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical pharmacokinetics</i> 55(4) 409–418. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0326-7&quot;>10.1007/s40262-015-0326-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26369775/&quot;>https://pubmed.ncbi.nlm.nih.gov/26369775</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BC03;
